This section includes information and resources about Stroke Prevention in Atrial Fibrillation (AF) for journalists: Boehringer Ingelheim press releases, background information, related press kits and a collection of images and videos. For additional information please visit NEWSCENTRE.
Many Atrial Fibrillation patients at high risk of stroke fail to receive guideline-recommended oral anticoagulant treatment- For Non-US/Non-UK/Non-Canadian Media
Boehringer Ingelheim submits applications for approval of idarucizumab*, specific reversal agent to dabigatran etexilate (Pradaxa®), to EMA, FDA and Health Canada- For Non-US/Non-UK Media
First trial of a novel oral anticoagulant starts in prevention of recurrent stroke due to a blood clot of undetermined source- For Non-US/Non-UK/Non-Canadian Media
New data show specific antidote idarucizumab* reverses dabigatran-induced anticoagulation also in elderly and renally impaired volunteers- For Non-US/Non-UK/Non-Canadian Media
Two new, large scale real-world analyses show fewer major bleeds and strokes with Pradaxa® than with warfarin- For Non-US/Non-UK/Non-Canadian Media